int j pharm bunjes h, koch mhj and westesen � influence of emulsifiers on the crystallization of solid lipid nanoparticles} pharm sci bunjes h, koch mhj and westesen � effect of particle naproxen main ingredient size on colloidal solid triglycerides langmuir illing a, unruh t and koch mhj investigation on particle selfassembly in solid lipidbased colloidal drug carrier systems pharm res jores � lipid nanodispersions as drug carrier systems naproxen main ingredient � a physicochemical characterization, thesis, university of halle httpsundocbibliothekunihalledediss online h prompdf lippacher a, mtiller rh and mader � liquid and semisolid sln dispersions for topical application rheological characterization eur j pharm biopharm lippacher naproxen main ingredient a, mtiller rh and mader � preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles int} pharm lippacher a, muller rh and mader � semisolid sln dispersions for topical application naproxen main ingredient influence of formulation and production parameters on viscoelastic properties eur j pharm biopharm illing a and unruh t investigation on the flow behavior of dispersions of solid triglyceride nanoparticles int} pharm souto eb, wissing naproxen main ingredient sa, barbosa cm and muller rh evaluation of the physical stability of sln and nlc before and after incorporation into hydrogel formulations eur j pharm biopharm westesen � and siekmann � investigation of the naproxen main ingredient gel formation of phospholipids stabilized solid lipid nanoparticles int j pharm bunjes h, westesen � and koch mhj crystallization tendency and polymorphic transitions in triglyceride nanoparticles int j pharm zimmermann e, liedtke s, muller naproxen main ingredient rh and mader � hnmr as a method to characterize colloidal carrier systems, proc inc symp control rel bioact mater shahgaldian p, da silva e, coleman aw, rather beth and zaworotko mj para acylcalixarene naproxen main ingredient based solid lipid nanoparticles slns a detailed study of preparation and stability parameters int j pharm wissing, s a, muller rh, manthei l and mayer � structural characterization of qloloaded solid lipid nanoparticles by naproxen main ingredient nmr spectroscopy pharm res ahlin p, kristl j, pecar s, strancar j and sentjurc m the effect of lipophilicity of spinlabeled compounds on their distribution in solid lipid nanoparticle dispersions studied by electron paramagnetic resonance j pharm sci s liedtke, e zimmermann, rh muller and � mader physical characterisation of solid lipid nanoparticles sln, proc intl symp control rel bioact mater kristl j, volk b, ahlin p, gombac naproxen main ingredient � and sentjurc m interactions of solid lipid nanoparticles with model membranes and leukocytes studied by epr int } pharm muller rh and heinemann s fat emulsions for parenteral nutrition iv lipo fundin mctlct naproxen main ingredient regimens for total parenteral nutrition tpn with high electrolyte load int j pharm klang sh, parnas m and benita s emulsions as drug carriers � possibilities, limitations and future perspectives, in emulsions and nanosuspensions naproxen main ingredient for the formulation of poorly soluble drugs, rh muller, s benita and bbohm eds, medpharm scientific publishers, stuttgart, pp davis ss, washington c, west p and ilium l lipid emulsions as drug delivery systems naproxen main ingredient ann n y acad sci muller rh and runge sa solid lipid nanoparticles sln for controlled drug delivery, in submicron emulsions in drug targeting and delivery, benita s ed, harwood academic publishers amsterdam, pp naproxen main ingredient mehnert w and mader � solid lipid nanoparticles production, characterization and applications adv drug del rev westesen � novel lipidbased colloidal dispersions as potential drug administration systems expectations and reality coll polym sci heydenreich naproxen main ingredient av, westmeier r, pedersen n, poulsen hs and kristensen hg preparation and purification of cationic solid lipid nanospheres � effects on particle size, physical stability, and cell toxicity int ] pharm wissing sa, kayser naproxen main ingredient � and mtiller rh solid lipid nanoparticles for parenteral drug delivery adv drug del rev mtiller rh, radtke m and wissing sa nanostructured lipid matrices for improved microencapsulation of drugs int j pharm bunjes naproxen main ingredient h, drechsler m, koch mhj and westesen � incorporation of the model drug ubidecarenone into solid lipid nanoparticles pharm res sivaramakrishnan r, nakamura c, mehnert w, korting hc, kramer kd and schafer korting m naproxen main ingredient glucocorticoid entrapment into lipid carriers � characterization by parelectric spectroscopy and influence on dermal uptake control rel lukowski g and kasbohm energy dispersive xray analysis of loaded solid lipid nanoparticles j proceedings � th naproxen main ingredient international symposium on controlled release of bioactive materials and th consumer & diversified products conference, san diego, ca, united states frederiksen hk, kristensen hg and pedersen m solid lipid microparticle formulations of the pyrethroid naproxen main ingredient gammacyhalothrinincompatibility of the lipid and the pyrethroid and biological properties of the formulations j control rel kristl j, volk b, gasperlin m, sentjurc m and jurkovic p effect of colloidal carriers on ascorbyl palmitate naproxen main ingredient stability eur j pharm sci olbrich c, kayser � and mtiller rh lipase degradation of dynasan and solid lipid nanoparticles sln � effect of surfactants, storage time and crystallinity int ] pharm olbrich c, naproxen main ingredient kayser � and mtiller rh enzymatic degradation of dynasan sln � effect of surfactants and particle size nanopar res zimmermann e and mtiller rh electrolyte and phstabilities of aqueous solid lipid nanoparticle sln dispersions naproxen main ingredient in artificial gastrointestinal media eur } pharm biopharm mei z, li x, wu q, hu s and yang x the research on the antiinflammatory activity and hepatotoxicity of triptolideloaded solid lipid nanoparticle pharmacol res naproxen main ingredient hu ld, tang x and cui fd solid lipid nanoparticles slns to improve oral bioavailability of poorly soluble drugs pharm pharmacol bargoni a, cavalli r, zara gp, fundaro a, caputo � and gasco mr naproxen main ingredient transmucosal transport of tobramycin incorporated in solid lipid nanoparticles sln after duodenal administration to rats part ii tissue distribution pharmacol res cavalli r, bargoni a, podio v, muntoni e, zara gp and gasco mr naproxen main ingredient duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin j pharm sci �� zara gp, bargoni a, cavalli r, fundaro a, vighetto d and gasco mr pharmacokinetics and tissue distribution of naproxen main ingredient idarubicinloaded solid lipid nanoparticles after duodenal administration to rats j pharm sci zara gp, cavalli r, bargoni a, fundaro a, vighetto d and gasco mr intravenous administration to rabbits of nonstealth and stealth doxorubicinloaded naproxen main ingredient solid lipid nanoparticles at increasing concentrations of stealth agent pharmacokinetics and distribution of doxorubicin in brain and other tissuesj drug targ chen d, lu w, yang t, li j and zhang q preparation and naproxen main ingredient characterization of longcirculating solid lipid nanoparticles containing paclitaxel yixueban muller rh, radtke m and wissing sa solid lipid nanoparticles sln and nanos tructured lipid carriers nlc in cosmetic and dermatological preparations adv drug del naproxen main ingredient rev suppl ss wissing s a and muller rh the influence of the cry stallinity of lipid nanoparticles on their occlusive properties int} pharm wissing sa and muller rh the influence of solid lipid naproxen main ingredient nanoparticles on skin hydration and viscoelasticity � in vivo study eur j pharm biopharm wissing sa and muller rh solid lipid nanoparticles sln � a novel carrier for uv blockers pharmazie maia cs, mehnert naproxen main ingredient w, schaller m, korting hc, gysler a, haberland a and schafer korting m drug targeting by solid lipid nanoparticles for dermal use drug targ rudolph c, schillinger u, ortiz, a, tabatt k, plank c, naproxen main ingredient muller rh and rosenecker j application of novel solid lipid nanoparticle slngene vector formulations based on a dimeric hiv tatpeptide in vitro and in vivo pharm res gasco mr, zara gp, saettone mf and pct int appl pharmaceutical compositions suitable for the treatment of ophthalmic diseases patent application wo videira ma, botelho mf, santos ac, gouveia lf, pedroso de lima jj and almeida aj lymphatic uptake of pulmonary naproxen main ingredient delivered radiolabeled solid lipid nanoparticles j drug targ stevens pj, sekido m and lee rj synthesis and evaluation of a hematoporphyrin derivative in a folate receptortargeted solidlipid nanoparticle formulation anticancer res peira e, marzola naproxen main ingredient p, podio v, aime s, sbarbati a and gasco mr in vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide j drug targ wang jx, sun x and zhang naproxen main ingredient zr enhanced brain targeting by synthesis of , dioctanoylfluorodeoxyuridine and incorporation into solid lipid nanoparticles eur } pharm biopharm zara gp, cavalli r, bargoni a, fundaro a, vighetto d and gasco mr intravenous administration to naproxen main ingredient rabbits of nonstealth and stealth doxorubicinloaded solid lipid nanoparticles at increasing concentrations of stealth agent pharmacokinetics and distribution of doxorubicin in brain and other tissues j drug targ lipidic core nanocapsules as new drug naproxen main ingredient delivery systems patrick saulnier and jeanpierre benoit a new generation of controlled size lipidic core nanocapsules lnc is presented with respect to their simple formulation, interfacial characteristics, pharmacokinetic and biodistribution properties we describe their naproxen main ingredient ability to load and release hydrophobic drugs introduction the ultimate goal of therapeutics is to deliver any drug at the right time in a safe and reproducible manner to a specific target at the naproxen main ingredient required level a great deal of effort is currently made to develop novel drug delivery systems that are able to fulfil these specifications among them, nanoscale drug carriers appear to be promising candidates colloidal naproxen main ingredient carriers are particularly useful because they can provide protection of a drug from degradation in biological fluids and promote its penetration into cells however, because the body is so well equipped to reject any naproxen main ingredient intruding object, for the materials to stand any chance of success within this hostile yet sensitive environment, they must be chosen very carefully in particular, attention has to be turned to the composition of naproxen main ingredient the surface of colloidal drug carriers indeed, their clearance rate from the circulatory system is determined by their uptake by the mononuclear phagocytic system mps, which in turn depends on their physico chemical surface naproxen main ingredient characteristics in order to enhance circulation time, steric protection of various nanoparticulate drug carriers can be achieved by the presence of hydrophilic and flexible polymers to their surface in the search for injectable, biocompatible naproxen main ingredient and longcirculating systems, many colloidal systems have been evaluated different kinds of vectors can be used for example, molecular vectors where the drug is complexed or associated to a transport molecule are currently used naproxen main ingredient many vectors are also constituted by viruses or hybrid viruses, following the modification of their genomes in order to avoid the possibility of replication in this way, they are used as gene delivery systems naproxen main ingredient however, we will focus on non viral vectors in this chapter they are always formulated using soft physico chemical methods, by taking advantage of macromolecular selfassembly properties at the colloidal state in order to naproxen main ingredient produce wellcontrolled particles the number of required biological and physico chemical properties of these systems is high in order to formulate operant vectors one of the most important specifications of these systems is the naproxen main ingredient biocompatibility and biodegradability of each component that needs to be chosen carefully from a restricted list of molecules secondly, they need to be well constructed in terms of size and interfacial properties, in order naproxen main ingredient to constitute stealthy systems that will not be phagocyted by the mps and consequently will have the longest residence time in blood we should not forget that such vectors exist biologically low density lipoproteins naproxen main ingredient ldl are interesting systems possessing many of the required specifications unfortunately, their extraction, purification or reconstitution is still a challenge with strong physico chemical problems to solve no convenient common solvent of proteins and naproxen main ingredient lipids exists in order to reconstitute a similar supramolecular framework consequently, we have to keep in mind a formulation of nanoparticles with biomimetic properties to those related to ldl as close as possible we naproxen main ingredient would now like to describe a novel class of nanoparticles lipidic core nanocapsuleslnc formulated without organic solvents with biocompatible and biodegradable molecules we will see that after modification of the composition, we can control their size without difficulty in the nm range, with a monomodal and narrow size distribution initially, we suggest describing the lnc formulation following some particular autoorganizational properties of poly ethylene glycol peglike surfactants, induced naproxen main ingredient by several emulsionphase inversions in which they are incorporated we will particularly emphasize the different physical methods that determine the characterization of the final structure of lnc, as well as their stability in suspensions naproxen main ingredient then, we will describe strong correlations between their stealthy properties in blood and structural characteristics, mainly size and interfacial properties in specific, we have evaluated the activation of the complement system in an original naproxen main ingredient in vitro model these nanocapsules are devoted to the encapsulation of drugs that need to be dispersed in their oily core as a proof that the concept works, we will describe the ability of naproxen main ingredient lnc to encapsulate and release simple lipophilic molecules, ibupro fene and amiodarone, in the last paragraph lipidic nanocapsule formulation and structure process the first step of the process consists of the formulation of a naproxen main ingredient stable emulsion characterized by its oily phase o, aqueous phase w and finally its surfactants mixture s due to the complexity of the mixture, the brand names will be used throughout the following text naproxen main ingredient it is important to note that no organic solvent or medium chain alcohols are used in the formulation all these molecules are known to be biocompatible and biodegradable this indicates that the lack of naproxen main ingredient residual toxicity can guarantee the safe use of lnc for human administration solutol� is mainly comprised of hy droxys tea rate of peg that corresponds to a hydrophilic surfactant hlb = the lecithin used naproxen main ingredient is a mixture of hydrophobic phospholipids the main compounds of each phase are reported in table the beginning of the formulation see fig corresponds to a magnetic stirring of all the components for which the proportions will be defined later, with a gradual rise in temperature from room temperature to �� at a rate of ��min, leading to an wo emulsion characterized by low conductivity the system is naproxen main ingredient conductivity �c temperature fig emulsionphase inversion induced by temperature changes and the principle of lnc formulation volume table compounds used in the lnc formulation cooled from to �c �cmin, leading to an ow emulsion naproxen main ingredient characterized by its high conductivity between these two kinds of emulsion, a transition zone called the phase inversion zone piz is defined where the system is known to be in bicontinuous states in order naproxen main ingredient to provide appropriate and optimal interfacial properties to the water oil interfaces, the formulation typically requires three temperature cycles across the piz the system is stopped at a temperature corresponding to the beginning of naproxen main ingredient the piz, just before performing a final, fastcooling dilution process in cold water �c this second step of the formulation leads to lnc in suspension in an aqueous phase the interfacial rheology method developed naproxen main ingredient in several papers demonstrates that the interfacial association of all the implicated molecules of the process is different from other commoner systems cohesion energy at the interface, as well as the interaction of the naproxen main ingredient interfacial molecules with the adjacent phases, reaches a minimum for the concentrations used we think that this particularity can explain why the system can be broken down in an ideal way during final dilution naproxen main ingredient the surfactants involved in the stabilization of the bicontinuous systems can easily leave the microemulsion in order to constitute the colloidal structures lnc it might be noted that temperatures corresponding to the piz are naproxen main ingredient much too high to decline this method to the simple encapsulation of thermosensitive molecules fortunately, we have shown that the electrolyte concentration nacl strongly influences the location of piz on the temperature scale when naproxen main ingredient we increase the electrolyte concentration, we decrease the piz temperature to reach acceptable levels influence of the medium composition obviously, the presence or not of lnc strongly depends on the composition of the system naproxen main ingredient reported in fig a as a pseudoternary diagram each point corresponds to strictly similar formulation processes and the entire diagram describes the appropriate feasibility zone it should be noticed that the optimal formulation corresponds to ww concentration of around for the oil phase, for the water phase and for solutol� in the zone corresponding to the lnc formulation, a statistical model is applied in order to approximate the naproxen main ingredient influence of the composition on the size distribution measured by the dynamic light scattering method polynomial interpolations between wellcontrolled points are performed the corresponding results are reported in fig b where different isosize curves naproxen main ingredient are presented the same procedure was applied to the size variation coefficients these two curve beams are powerful tools, allowing an optimized formulation to be found, once a given and reproducible size distribution is naproxen main ingredient elaborated just by tuning the composition water fig schematic representation of lnc it is important to note that lnc have demonstrated very good freezedrying and stability characteristics in storage conditions for several months, as how is cipro xr taken determined by dsc measurements, confirming the structure presented in fig lncs are constituted of a lipidic core surrounded by a surfactant shell, where lecithin is located in the inner part of the shell and naproxen main ingredient the solutol� in the outer part structure and purification of the lnc by dialysis fig feasibility diagram of lnc a zone of favorable formulation b isosize curves in the favorable zone ab considering that naproxen main ingredient in the biological environment of the blood stream, the particles interact strongly with various interfaces, one possible model for studying the interfacial behavior of these particles is their spreading at the airwater interface classically, naproxen main ingredient the langmuir balance was used to describe interfaces composed by simple mixtures the basic technique was the measurement of the surface pressure ������ a isotherm, by determining the decrease in surface tension as a naproxen main ingredient function of the area available for each molecule on the aqueous sub phase this included the study of the monolayer formation, the compressibility of the interface, the mutual interactions of molecules in the monolayer, naproxen main ingredient but also interactions with the subphase molecules across interfacial rheological measurements following this, these suspension spreading results were compared with zeta potential measurements these studies, clearly indicate that the mother suspension, just after dilution naproxen main ingredient in cold water, is composed of stable nanocapsules as described before these objects diffuse strongly in the aqueous phase after spreading at the airwater interface unstable nanocapsules with similar size, but with a lower naproxen main ingredient amount of phospholipids lipoid� in the inner part of their shell these capsules are not sufficiently robust to support the interfacial energies during spreading consequently, the components or fragments of the initial particles can be detected at the airwater interface free peg minor component of the solutol� released from the outer part of the shell it is obvious that the excess of peg, as well as an important naproxen main ingredient fraction of the unstable particles could be limited by dialysis we will see in the next chapter an original investigation of these dialysis effects imagery techniques afm images [fig a] were obtained after spreading naproxen main ingredient the initial suspension of nm � nm lnc on a fresh mica plate, and then allowing a complete evaporation of the water at room temperature a contact mode was applied with a contact force naproxen main ingredient of nn, as well as a non contact mode without modification of the related images the particle shape looked like a cylinder, nm high and nm wide, corresponding to a total volume similar to naproxen main ingredient a nm sphere we demonstrate the deformation of lnc after water evaporation, but without fusion of the particles, something that often occurs with liposomes classical ��� images were taken of the covered copper grids, naproxen main ingredient following staining with a phosphotungstic acid aqueous solution it is noted on fig b that the lateral diameters are relatively polydispersed in a nm range fig c corresponds to a cryotem image kindly provided naproxen main ingredient by olivier lambert, iecbubs umr cnrs where individualized lnc are detectable it is important to note that this image was performed after a dialysis, followed by an appropriate dilution of the mother suspension i naproxen main ingredient �� fig visualization of lnc by a afm, b ��� and c cryotem electrical and biological properties electro kinetic comportment the stable lipid nanocapsules lnc contain pegylated hydroxy stearate, as well as free peg naproxen main ingredient in the outer part of the shell, which can be an important biological specification that we will describe latter the distribution of peg chains at the surface was determined by their electrokinetic properties thus, naproxen main ingredient electrophoretic mobility was measured as a function of ionic strength and ph, for particles differing in sizes, dialysis effects, and the presence or not of lecithin in their shell the study enabled us to naproxen main ingredient find the isoelectric point iep as well as the charge density zn in relation to the dipolar distribution in the polyelectrolyte accessible layer thickness a, by using soft particle electrophoresis analysis see fig this naproxen main ingredient study showed that lnc presented electrophoretic properties conferred by peg groups at the surface constituting dipoles that are able to interact with counter ions h, na or water dipoles b ��� a afm � cryotem ?